image credit- shutterstock
China-based Sanyou Biopharmaceutical and Guangzhou Baiyunshan Xihe Health Pharmaceutical have jointly announced the official signing of a strategic cooperation agreement. This partnership will focus on the co-development of novel radiopharmaceuticals and radiodiagnostic products, aiming to integrate their respective core strengths in AI-driven innovative drug molecule discovery and the full industrial value chain of nuclear medicine.
Together, the two parties seek to build an end-to-end innovation chain spanning from target molecule discovery to clinical translation of radiopharmaceuticals, delivering more transformative solutions for precision oncology diagnosis and therapy.
The development of radiopharmaceuticals and radiodiagnostic products places extremely high demands on the precision, stability, and druggability of targeting molecules. This strategic collaboration is based on both parties' deep insight into the nuclear medicine industry trends and strong mutual recognition of each other's technological capabilities.
Sanyou Bio will leverage its globally leading AI-Super trillion antibody/molecule libraries (AI-STAL) and its Sanyou AI-Drug Accelerator (SAI-DA) to provide source innovation power for the discovery and optimisation of high-performance antibodies and targeting molecules against specific targets.
Baiyunshan Xihe will rely on its end-to-end capabilities in novel medical radionuclide production, GMP manufacturing, and clinical translation to advance partnered molecules into radiolabeling, in vitro and in vivo evaluation, and preclinical studies, thereby accelerating the industrialisation of innovative radiopharmaceuticals and radiodiagnostic products.
